5,477
edits
Weight loss injections Philadelphia: Difference between revisions
→Retatrutide safety and access note
No edit summary |
|||
| Line 192: | Line 192: | ||
In May 2026, Lilly announced phase 3 TRIUMPH-1 results in which participants on 12 mg retatrutide lost an average of 70.3 pounds, or 28.3%, over 80 weeks.{{cite web|url=https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss|title=Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial|publisher=Eli Lilly and Company|date=May 21, 2026|accessdate=June 30, 2026}} | In May 2026, Lilly announced phase 3 TRIUMPH-1 results in which participants on 12 mg retatrutide lost an average of 70.3 pounds, or 28.3%, over 80 weeks.{{cite web|url=https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss|title=Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial|publisher=Eli Lilly and Company|date=May 21, 2026|accessdate=June 30, 2026}} | ||
Please note '''retatrutide is investigational''' as of June, 2026 and is off-label use if prescribed. W8MD can educate the patients on this and other [[GLP-1 weight loss injections]]. | |||
''' | |||
W8MD can educate patients | |||
==Traditional prescription weight-loss medications at W8MD== | ==Traditional prescription weight-loss medications at W8MD== | ||